Who was studied, and how
Four numbers in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 23 other studies
people with type 2 diabetes, in this paper
The trial randomly assignedassigned by chance
canagliflozin 100 mg
placebo
Probably lowered long-term blood sugar−0.63
Reported lower body weight, no range given−2.23
randomisedThe trial randomly assignedassigned by chance
canagliflozin 300 mg
placebo
Probably lowered long-term blood sugar−0.80
Reported lower body weight, no range given−3.00
randomisedthe abstract, start to end
… of glycosylated hemoglobin (HbA1c) were -0.63 (95% CI: -0.77, -0.49) and -0.80 (95% CI: -0.98, -0.62) for …
… with that of placebo, with a WMD of -2.23 and -3.00 in percent changes (P < 0.001 …
← favours treatmentfavours comparator →
could be chanceNo interval given · direction only, strength unknown
Glycosylated hemoglobin (HbA1c)canagliflozin 100 mg vs placebo
−0.63−0.77 to −0.49
Glycosylated hemoglobin (HbA1c)canagliflozin 300 mg vs placebo
−0.80−0.98 to −0.62
Body weightcanagliflozin 100 mg vs placebo
−2.23
Body weightcanagliflozin 300 mg vs placebo
−3.00
SGLT2 inhibitorsGlycemic controlBody weight & composition
SGLT2 inhibitors × body weight & compositionhelps?settled
unlikelylikely
0.98not counted
SGLT2 inhibitors × glycemic controlhelps?replicated
unlikelylikely
0.92not counted
← favours treatmentfavours comparator →
1 / 6